Novo Nordisk A/S (NVO) unveiled real-world data on Tuesday indicating that patients who increased their semaglutide dose experienced fewer major cardiovascular events than patients who switched to Eli Lilly and Co.’s (LLY) rival tirzepatide. The retrospective analysis drew on records from 63, although the available source ends before specifying what the figure refers to.